NCT03020771View on ClinicalTrials.gov

Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Crimean-Congo Hemorrhagic Fever
Interventions
BIOLOGICAL

KIRIM-KONGO-VAX

Crimean-Congo Hemorrhagic Fever Vaccine

OTHER

Placebo

All Listed Sponsors
collaborator

MonitorCRO

INDUSTRY

lead

The Scientific and Technological Research Council of Turkey

OTHER

NCT03020771 - Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans | Biotech Hunter | Biotech Hunter